Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 03

1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustion

Date

14 Sep 2024

Session

Poster session 03

Presenters

Bo Cheng

Citation

Annals of Oncology (2024) 35 (suppl_2): S674-S711. 10.1016/annonc/annonc1596

Authors

B. Cheng1, X. Shang2, H. Wang3

Author affiliations

  • 1 Radiation Oncology, Qilu of Shandong University, 250117 - Jinan/CN
  • 2 Clinical Oncology, Shandong Cancer Hospital Affiliated to Shandong University, 250117 - Jinan/CN
  • 3 Internal-medicine Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 250117 - Jinan/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1019P

Background

The efficacy of immune checkpoint inhibitors (ICIs) in SMARCA4 mutant non-small cell lung cancer (NSCLC) is limited. CD8+ T cell exhaustion plays an important role in damaging anti-tumor immunity, but the molecular mechanisms remain unclear.

Methods

We compared the survival difference between patients with SMARCA4 mutation and wild type. The RNA sequencing of CD8+T cells sorted from tumor tissues was performed. The SMARCA4 mutant-H1299 cells were implanted into the left flank of the NSG mice. 2×107 human PBMCs were separated and injected intravenously into NSG mice to establish humanized NSG mouse models. Anti-PD-1 of Bispecific PD1-IL2 antibody were given intraperitoneally. The frequencies and phenotypes of CD8+T cells in mouse spleens and blood were detected by flow cytometry while those in tumor tissues were determined by multiplex immunofluorescence (mIF). The mIF staining was performed to validate differences of CD8+ T cells exhaustion phenotype between SMARCA4 mutant and wild-type patient tissues.

Results

Treatment with ICIs could not improve outcomes in patients with SMARCA4 mutations (P = 0.754). The analysis of RNA sequencing showed that the production of interleukin-2 (IL-2) was significantly reduced in CD8+T cells of SMARCA4 mutant Lewis lung carcinoma (P < 0.001). The analysis of mIF revealed that the infiltration of PD1+CD8+, LAG3+CD8+, TIM3+CD8+ T cells increased in SMARCA4 mutant tumor tissues. We found that a high level of IL-2 leads to the persistent activation of STAT5 in CD8+ T cells. Bispecific PD1-IL2 antibody enhanced anti-tumor immunity and suppressed tumor progression by reversing CD8+T cells exhaustion.

Conclusions

The PD1-IL2 bispecific antibody could reverse CD8+T cell exhaustion to enhance anti-tumor immunity in SMARCA4 mutant NSCLC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

H. Wang.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.